Verastem (VSTM)
(Delayed Data from NSDQ)
$2.27 USD
-0.22 (-8.84%)
Updated Aug 14, 2024 03:59 PM ET
After-Market: $2.27 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Brokerage Reports
0 items in cart
Verastem, Inc. [VSTM]
Reports for Purchase
Showing records 241 - 260 ( 266 total )
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
1Q13 Results; Going to FAK with Mesothelioma; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
2012 Results; All Engines Engaged, Reiterate Buy and $18 PT
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
Targeting the Root of the Tumor, Initiating Coverage at Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
Positions FAK and Mesothelioma as Lead Clinical Program During R&D Update
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
Positions FAK and Mesothelioma as Lead Clinical Program During R&D Update
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
Verastem Doubles Down on FAK, Picking Up a Phase II-Ready Asset for a Pittance
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
Verastem Doubles Down on FAK, Picking Up a Phase II-Ready Asset for a Pittance
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
Open Road Ahead for VS-507 as FDA Accepts pCR as an Approvable Endpoint
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
Open Road Ahead for VS-507 as FDA Accepts pCR as an Approvable Endpoint
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
FY1Q12 Earnings; Board Additions Bolster Credentials in the CSC Drug Space
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M
Company: Verastem, Inc.
Industry: Medical - Biomedical and Genetics
FY1Q12 Earnings; Board Additions Bolster Credentials in the CSC Drug Space
Provider: RODMAN & RENSHAW, CO.
Analyst: KING M